2-hydroxy-2-(4-methylthiazol-2-yl)propanehydrazide | 1251929-90-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-hydroxy-2-(4-methylthiazol-2-yl)propanehydrazide
• 英文别名: 2-hydroxy-2-(4-methyl-1,3-thiazol-2-yl)propanehydrazide
• CAS: 1251929-90-4
• 化学式: C₇H₁₁N₃O₂S
• 分子量: 201.249
• InChiKey: JWNBIPXBENICMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  117
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-hydroxy-2-(4-methylthiazol-2-yl)propanehydrazide 在 硫酸 作用下， 以 乙醇 为溶剂， 反应 5.0h， 生成 1-(5-(1-(2,6-difluorobenzyl)-1H-pyrazol-3-ylamino)-1,3,4-thiadiazol-2-yl)-1-(4-methylthiazol-2-yl)ethanol
  参考文献：
  名称：

  (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE AND (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE COMPOUNDS

  摘要：

  一个由Formula (I)组成的化合物 其中：X为N且Y为CR5，或者X为C且Y为S；Z从N和CH中选择；R1从H和Me中选择；R2从H、OH、OMe和Me中选择；每个R3独立地从C1-3烷基、F、Cl、Br、CF3和NH2中选择；R4从Me、CF3、NO2和CHF2中选择；R5从H、Me和CHF2中选择；R6从H和Me中选择；p为0-3，提供了含有它们的组合物，它们在治疗中的使用，例如在结核病治疗中的使用，以及制备这类化合物的方法。

  公开号：

  US20120095064A1
• 作为产物：
  描述：

  2-羟基-2-(4-甲基-1,3-噻唑-2-基)丙酸乙酯 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 3.0h， 以100%的产率得到2-hydroxy-2-(4-methylthiazol-2-yl)propanehydrazide
  参考文献：
  名称：

  3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS

  摘要：

  公式（I）的化合物或其药用盐：其中：Het是5至10成员的杂环芳香环；X为N且Y为CR5；或X为C且Y为S；Z从N和CH中选择；R1从H和C1-2烷基中选择；R2从H、C1-2烷基、OH、—CH2OH和C1-2烷氧基中选择；每个R3独立选择自OH、C1-3烷基、F、Cl、Br、NH2和C1-3烷氧基；R4从C1-3烷基和卤代C1-3烷基中选择；R5从H、C1-3烷基和卤代C1-3烷基中选择；R6和R7要么i）各自独立选择自H、C1-3烷基和C1-3烷氧基；要么ii）R6和R7与它们附着的环一起形成9成员双环环；p为0-3；RA从H和C1-3烷基中选择，提供了含有它们的组合物，它们在治疗中的使用，例如在结核病的治疗中，并提供了这类化合物的制备方法。

  公开号：

  US20130203802A1

文献信息

• [EN] 3 -AMINO- PYRAZOLE DERIVATIVES USEFUL AGAINST TUBERCULOSIS<br/>[FR] DÉRIVÉS DE 3-AMINO-PYRAZOLE UTILES CONTRE LA TUBERCULOSE
  申请人：GLAXO GROUP LTD

  公开号：WO2012049161A1

  公开（公告）日：2012-04-19

  A compound of Formula (I) or a pharmaceutically acceptable salt thereof: (I), Wherein: Het is a 5 to 10-membered heteroaromatic ring; Either X is N and Y is CR5; or X is C and Y is S; Z is selected from N and CH; R1 is selected from H and C1-2alkyl; R2 is selected from H, C1-2alkyl, OH, -CH2OH and C1-2alkoxy; Each R3 is independently selected from OH, C1-3alkyl, F, Cl, Br, NH2, and C1-3alkoxy; R4 is selected from C1-3alkyl and haloC1-3alkyl; R5 is selected from H, C1-3alkyl and haloC1-3alkyl; R6 and R7 are either i) each independently selected from H, C1-3alkyl and C1-3alkoxy; or ii) R6 and R7 together with the ring to which they are attached form a 9-membered bicylic ring; p is 0-3; and RA is selected from H and C1-3alkyl, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.

  化合物的化学式（I）或其药学上可接受的盐：（I），其中：Het是一个5到10个成员的杂芳环；X是N且Y是CR5；或X是C且Y是S；Z从N和CH中选择；R1从H和C1-2烷基中选择；R2从H，C1-2烷基，OH，-CH2OH和C1-2烷氧基中选择；每个R3独立地从OH，C1-3烷基，F，Cl，Br，NH2和C1-3烷氧基中选择；R4从C1-3烷基和卤代C1-3烷基中选择；R5从H，C1-3烷基和卤代C1-3烷基中选择；R6和R7要么i）各自独立地从H，C1-3烷基和C1-3烷氧基中选择；要么ii）R6和R7与它们附着的环一起形成一个9个成员的双环环；p为0-3；RA从H和C1-3烷基中选择，提供了含有它们的组合物，它们在治疗中的用途，例如在结核病治疗中的用途，以及这类化合物的制备方法。
• [EN] ( PYRAZOL-3-YL) -1, 3, 4-THIADIAZOL-2-AMINE AND ( PYRAZOL-3-YL) -1, 3, 4-THIAZOL-2-AMINE COMPOUNDS<br/>[FR] COMPOSÉS DE (PYRAZOL-3-YL)-1,3,4-THIADIAZOL-2-AMINE ET DE (PYRAZOL-3-YL)-1,3,4-THIAZOL-2-AMINE
  申请人：GLAXO GROUP LTD

  公开号：WO2010118852A1

  公开（公告）日：2010-10-21

  wherein: either X is N and Y is CR5 or X is C and Y is S; Z is selected from N and CH; R1 is selected from H and Me; R2 is selected from H, OH, OMe and Me; each R3 is independently selected from C1-3alkyl, F, Cl, Br, CF3 and NH2; R4 is selected from Me, CF3, NO2 and CHF2; R5 is selected from H, Me and CHF2; R6 is selected from H and Me; and p is 0-3, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.

  提供其中的化学式：其中，要么X是N且Y是CR5，要么X是C且Y是S；Z从N和CH中选择；R1从H和Me中选择；R2从H、OH、OMe和Me中选择；每个R3独立地从C1-3烷基、F、Cl、Br、CF3和NH2中选择；R4从Me、 、NO2和CHF2中选择；R5从H、Me和 中选择；R6从H和Me中选择；p为0-3。提供了包含它们的组合物，它们在治疗中的应用，例如在结核病的治疗中，以及制备这些化合物的方法。
• 3-amino-pyrazole derivatives useful against tuberculosis
  申请人：Castro Pichel Julia

  公开号：US08779153B2

  公开（公告）日：2014-07-15

  A compound of Formula (I) or a pharmaceutically acceptable salt thereof: Wherein: Het is a 5 to 10-membered heteroaromatic ring; Either X is N and Y is CR5; or X is C and Y is S; Z is selected from N and CH; R1 is selected from H and C1-2alkyl; R2 is selected from H, C1-2alkyl, OH, —CH2OH and C1-2alkoxy; Each R3 is independently selected from OH, C1-3alkyl, F, Cl, Br, NH2, and C1-3alkoxy; R4 is selected from C1-3alkyl and haloC1-3alkyl; R5 is selected from H, C1-3alkyl and haloC1-3alkyl; R6 and R7 are either i) each independently selected from H, C1-3alkyl and C1-3alkoxy; or ii) R6 and R7 together with the ring to which they are attached form a 9-membered bicylic ring; p is 0-3; and RA is selected from H and C1-3alkyl, compositions containing them, their use in therapy, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.

  化合物的式子（I）或其药学上可接受的盐： 其中：Het是5至10个成员的杂环芳香环；X为N且Y为CR5，或者X为C且Y为S；Z从N和CH中选择；R1从H和C1-2烷基中选择；R2从H，C1-2烷基，OH，—CH2OH和C1-2烷氧基中选择；每个R3独立地从OH，C1-3烷基，F，Cl，Br，NH2和C1-3烷氧基中选择；R4从C1-3烷基和haloC1-3烷基中选择；R5从H，C1-3烷基和haloC1-3烷基中选择；R6和R7要么各自独立地从H，C1-3烷基和C1-3烷氧基中选择；要么R6和R7与它们附着的环一起形成一个9成员的双环；p为0-3；RA从H和C1-3烷基中选择，提供了含有它们的组成物，它们在治疗中的使用，例如在结核病的治疗中，以及这种化合物的制备方法。
• Design, Synthesis, and Evaluation of New Thiadiazole-Based Direct Inhibitors of Enoyl Acyl Carrier Protein Reductase (InhA) for the Treatment of Tuberculosis
  作者：Roman Šink、Izidor Sosič、Matej Živec、Raquel Fernandez-Menendez、Samo Turk、Stane Pajk、Daniel Alvarez-Gomez、Eva Maria Lopez-Roman、Carolina Gonzales-Cortez、Joaquin Rullas-Triconado、Inigo Angulo-Barturen、David Barros、Lluís Ballell-Pages、Robert J. Young、Lourdes Encinas、Stanislav Gobec

  DOI：10.1021/jm501029r

  日期：2015.1.22

  Mycobacterial enoyl acyl carrier protein reductase (InhA) is a clinically validated target for the treatment of tuberculosis infections, a disease that still causes the death of at least a million people annually. A known class of potent, direct, and competitive InhA inhibitors based on a tetracyclic thiadiazole structure has been shown to have in vivo activity in murine models of tuberculosis infection. On the basis of this template, we have here explored the medicinal chemistry of truncated analogues that have only three aromatic rings. In particular, compounds 8b, 8d, 8f, 8l, and 8n show interesting features, including low nanomolar InhA IC50, submicromolar antimycobacterial potency, and improved physicochemical profiles in comparison with the tetracyclic analogues. From this series, 8d is identified as having the best balance of potency and properties, whereby the resolved 8d S-enatiomer shows encouraging in vivo efficacy.
• Methyl-Thiazoles: A Novel Mode of Inhibition with the Potential to Develop Novel Inhibitors Targeting InhA in Mycobacterium tuberculosis
  作者：Pravin S. Shirude、Prashanti Madhavapeddi、Maruti Naik、Kannan Murugan、Vikas Shinde、Radha Nandishaiah、Jyothi Bhat、Anupriya Kumar、Shahul Hameed、Geoffrey Holdgate、Gareth Davies、Helen McMiken、Naina Hegde、Anisha Ambady、Janani Venkatraman、Manoranjan Panda、Balachandra Bandodkar、Vasan K. Sambandamurthy、Jon A. Read

  DOI：10.1021/jm4012033

  日期：2013.11.14

  InhA is a well validated Mycobacterium tuberculosis (Mtb) target as evidenced by the clinical success of isoniazid. Translating enzyme inhibition to bacterial cidality by targeting the fatty acid substrate site of InhA remains a daunting challenge. The recent disclosure of a methyl-thiazole series demonstrates that bacterial cidality can be achieved with potent enzyme inhibition and appropriate physicochemical properties. In this study, we report the molecular mode of action of a lead methyl-thiazole, along with analogues with improved CYP inhibition profile. We have identified a novel mechanism of InhA inhibition characterized by a hitherto unreported "Y158-out" inhibitor-bound conformation of the protein that accommodates a neutrally charged "warhead". An additional novel hydrophilic interaction with protein residue M98 allows the incorporation of favorable physicochemical properties for cellular activity. Notably, the methyl-thiazole prefers the NADH-bound form of the enzyme with a K-d of similar to 13.7 nM, as against the NAD(+)-bound form of the enzyme.